ESTRATÉGIAS DE TRATAMENTO PARA PÚRPURA TROMBOCITOPÊNICA TROMBÓTICA: : UMA REVISÃO INTEGRATIVA.

Matheus  Guedes Duarte; Andréia Tatiane Kremer

Authors

Matheus Guedes Duarte Centro Universitário Cenecista de Os´ório/RS
Andréia Tatiane Kremer Centro Universitário Cenecista de Os´ório/RS

Keywords:

Púrpura Trombocitopênica Trombótica, Estratégias de Tratamento, Plasmaférese, Proteína ADAMTS13, Troca de Plasma

Abstract

The main objective of this study is to review the recent literature regarding available strategies for the treatment of Thrombotic Thrombocytopenic Purpura (TTP). It includes the evolution of the ways of diagnosis, variations in therapeutic practices, and impacts on the prognosis. This is an integrative literature review, for which consultations were carried out on the PubMed and Scientific Electronic Library Online (SciELO) data platforms. The following English terms were used: Thrombotic Thrombocytopenic Purpura; Plasmapheresis; ADAMTS13 Protein; Plasma Exchange; Plasma Drugs; Immunosuppressive Agents. As a period, publications from the last five years (2017-2022) were defined. The search resulted in 18 selected articles, which were interpreted and their results were discussed, indicating advances in treatment strategies for PTT. Studies demonstrate the search for more effective treatments, especially those capable of reducing the length of hospital stay, the mortality rate, and dependence on plasma exchange (plasmapheresis). Thus, nowadays, the standard management of TT is a triple therapy consisting of the use of caplacizumab (recently approved), combined with plasmapheresis and immunosuppression (especially rituximab). The review also provides perspectives for future treatments that are still in the very early stages of testing, highlighting: emerging anti-vWF therapies and recombinant ADAMTS13 (rADAMTS13).

Author Biography

Matheus Guedes Duarte , Centro Universitário Cenecista de Os´ório/RS

Biomédico, mestre em Biologia Molecular e Celular pelo PPGBioSaúde/ULBRA através de bolsa CAPES, graduado na Universidade Luterana do Brasil-Canoas/RS através de bolsa integral do PROUNI, com habilitação em Análises Clínicas (Patologia Clínica) e Biologia Molecular. Registro CRBm5: 0893. Atualmente sou professor do curso de biomedicina no Centro Universitário CNEC de Osório e Responsável Técnico Substituto do Laboratório de Análises Clínicas da Santa Casa de Misericórdia de Porto Alegre, mas atuando na cidade de Santo Antônio da Patrulha, no hospital da cidade, o qual recentemente foi anexado ao complexo de hospitais. Sou professor convidado do curso de pos graduação em Hematologia e Banco de Sangue do Centro Universitário FSG. Contudo tive o prazer de trabalhar anteriormente no Laboratório do Hospital de Caridade de São Jerônimo-AFPERGS, na Fundação Hospitalar Getúlio Vargas (FHGV)/Tramandaí, no Hospital São Vicente de Paulo/Osório, nos Laboratórios Vitale/RS, nos Laboratórios Fontana/RS e no Hospital Santa Rita/Triunfo. Em 2015, tive minha primeira experiência docente ministrando a cadeira de Controle de Qualidade em Laboratórios, na UNICNEC/Osório no curso de pós-graduação em Ciências Biomédicas. Também atuo como profissional autônomo, realizando Assessoria e Consultoria Científica na área de Hematologia e Gestão da Qualidade Laboratorial para implementação de acreditação e certificação de sistemas da qualidade para laboratórios de análises clínicas.

References

ARROYO, José Luis. et al. Methylene blue-treated plasma, versus quarantine fresh frozen plasma, for acute thrombotic thrombocytopenic purpura treatment: Comparison between centres and critical review on longitudinal data. Transfus Apher Sci, [S. l.], v. 59, n. 4, p. 102771, ago. 2020. DOI: 10.1016/j.transci.2020.102771. Disponívelem:https://pubmed.ncbi.nlm.nih.gov/32605805/. Acesso em: 15 out. 2022.

AZEVEDO, Brunna Rafaela do Amaral; MOTA, Isabella de Souza; PAULA JÚNIOR, Milton Rego de. Terapias adicionais a plasmaférese como tratamento da púrpura trombocitopênica trombótica. VITTALLE - Revista de Ciências da Saúde, [S. l.], v. 32, n. 3, p. 247–256, 2020. DOI: 10.14295/vittalle.v32i3.11921. Disponível em: https://periodicos.furg.br/vittalle/article/view/11921. Acesso em: 21 nov. 2022.

BAE, Sung Hwa; KIM, Sung-Hyun. BANG, Soo-Mee. Recent advances in the management of immune-mediated thrombotic thrombocytopenic purpura. Blood Res, [S. l.], v. 57, n. s1, p. 37-43, abri. 2020. DOI: 10.5045/br.2022.2022005. Disponível em: https://pubmed.ncbi.nlm.nih.gov/35483924/. Acesso em: 15 out. 2022.

BAUER, Philippe R. et al. Plasma exchange in the intensive care unit: a narrative review. Intensive Care Med, [S. l.], v. 48, p. 1382-1396, 2022. DOI: 10.1007/s00134-022-06793-z. Disponível_em:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9372988/pdf/134_2022_Article_6793.pdf. Acesso em: 25 nov. 2022.

CANADIAN AGENCY FOR DRUGS AND TECHNOLOGIES IN HEALTH (CADTH). Clinical Review Report: Caplacizumab (Cablivi): Sanofi Genzyme, a division of Sanofi-Aventis Canada Inc. CADTH Common Drug Reviews, Toronto, 2020. Disponível em: https://pubmed.ncbi.nlm.nih.gov/33600100/. Acesso em: 15 out. 2022.

CHEN, Bin et al. Comparison of the efficacy and safety of caplacizumab versus placebo in thrombotic thrombocytopenic purpura: a meta-analysis and systematic review based on randomized controlled trials. Ann Transl Med, [S. l.], v. 10, n. 12, p. 657-667, jun. 2022. DOI: 10.21037/atm-22-2847. Disponível em: https://pubmed.ncbi.nlm.nih.gov/35845542/. Acesso em: 15 out. 2022.

COPPO, Paul. CUKER, Adam; GEORGE, James. Thrombotic thrombocytopenic purpura: Toward targeted therapy and precision medicine. Res Pract Thromb Haemost, [S. l.], v. 3, n. 1, p. 26-37, nov. 2018. DOI: 10.1002/rth2.12160. Disponível em: https://pubmed.ncbi.nlm.nih.gov/30656273/. Acesso em: 15 out. 2022.

DANE, Kathryn; CHATURVEDI, Shruti. Beyond plasma exchange: novel therapies for thrombotic thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program, [S. l.], n. 1, p. 539-547, 30 nov. 2018. DOI: 10.1182/asheducation-2018.1.539. Disponível em: https://pubmed.ncbi.nlm.nih.gov/30504355/. Acesso em: 15 out. 2022.

DUGGAN, Sean. Caplacizumab: First Global Approval. Drugs, [S. l.], v. 78, n. 15, p. 1639-1642, out. 2018. DOI: 10.1007/s40265-018-0989-0.Disponível_em:https://pubmed.ncbi.nlm.nih.gov/30298461/. Acesso em: 15 out. 2022.

FONSECA, Gabriel de Lima Machado da et al. Uma análise acerca das características da púrpura trombocitopênica trombótica: uma revisão de literatura. Revista Eletrônica Acervo Saúde, [S. l.], v. 15, n. 7, p. e10715, 30 jul. 2022. DOI: 10.25248/reas.e10715.2022. Disponível em: https://acervomais.com.br/index.php/saude/article/view/10715. Acesso em: 25 nov. 2022.

GRAÇA, Nuno et al. TTP: From empiricism for an enigmatic disease to targeted molecular therapies. Br J Haematol, [S. l.], v. 197, n. 2, p. 156-170, abri. 2022. DOI: 10.1111/bjh.18040. Disponível em: https://pubmed.ncbi.nlm.nih.gov/35146746/. Acesso em: 15 out. 2022.

GRAGNANO, Felice et al. The Role of von Willebrand Factor in Vascular Inflammation: From Pathogenesis to Targeted Therapy. Mediators Inflamm, [S. l.], v. 2017, p. 1-13, maio 2017. DOI: 10.1155/2017/5620314. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5467347/pdf/MI2017-5620314.pdf. Acesso em: 25 nov. 2022.

HANLON, Ashley; METJIAN, Ara. Caplacizumab in adult patients with acquired thrombotic thrombocytopenic purpura. Ther Adv Hematol, [S. l.], v. 11, p. 1-10, 7 fev. 2020. DOI: 10.1177/2040620720902904. Disponível em:https://pubmed.ncbi.nlm.nih.gov/32095224/. Acesso em: 15 out. 2022.

KNÖBL, Paul et al. Efficacy and safety of open-label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study. J Thromb Haemost, [S. l.], v. 18, n. 2, fev. 2020, p. 479-484. DOI: 10.1111/jth.14679. Disponível em: https://pubmed.ncbi.nlm.nih.gov/31691462/. Acesso em: 15 out. 2022.

KNÖBL, Paul. Thrombotic thrombocytopenic purpura. Memo, [S. l.], v. 11, n. 3, p. 220-226, 2018. DOI: 10.1007/s12254-018-0429-6. Disponível_em:https://pubmed.ncbi.nlm.nih.gov/30220931/. Acesso em: 15 out. 2022.

KUCUKYURT, Selin; ESKAZAN, Ahmet Emre. Assessment and Monitoring of Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura (iTTP): Strategies to Improve Outcomes. J Blood Med, [S. l.], v. 28, n. 11, p. 319-326, 2020. DOI: 10.2147/JBM.S205630. Disponível em: https://pubmed.ncbi.nlm.nih.gov/33061729/. Acesso em: 15 out. 2022.

MAQSOOD, Muhammad Haisum; RUBAB, Kinza; MAQSOOD, Muhammad Zaigham. Clinical Efficacy and Safety Profile of Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura. Cureus, [S. l.], v. 11, n. 7, p. e5263, 29 jul. 2019. DOI: 10.7759/cureus.5263. Disponível em: https://pubmed.ncbi.nlm.nih.gov/31576256/. Acesso em: 15 out. 2022.

MORALES-MONTOYA, Alejandra. Púrpura trombocitopénica trombótica. Med Int Méx, Cidad del Mexico, v. 35, n. 6, p. 906-911, nov./dez. 2019. DOI: 10.24245/mim.v35i6.2741. Disponível em: https://www.medigraphic.com/pdfs/medintmex/mim-2019/mim196i.pdf. Acesso em: 25 nov. 2022.

PICOD, Adrien; COPPO, Paul. Developments in the use of plasma exchange and adjunctive therapies to treat immune-mediated thrombotic thrombocytopenic purpura. Expert Rev Hematol, [S. l.], v. 12, n. 6, p. 461-471, jun. 2019. DOI: 10.1080/17474086.2019.1619170. Disponível em: https://pubmed.ncbi.nlm.nih.gov/31092093/. Acesso em: 15 out. 2022.

SCULLY, Marie et al. Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura. N Engl J Med, [S. l.], v. 380, n. 4, p. 335+346, 24 jan. 2019. DOI: 10.1056/NEJMoa1806311. Disponível em: https://pubmed.ncbi.nlm.nih.gov/30625070/. Acesso em: 15 out. 2022.

SILVA, Catarina Pereira da. Uso e prescrição off-label. Revista Jurídica Luso-Brasileira, Lisboa, v. 8, n. 2, p. 1595-1634, 2022. Disponível em: https://www.cidp.pt/revistas/rjlb/2022/2/2022_02_1595_1634.pdf. Acesso em: 06 nov. 2022.

SUKUMAR, Senthil; LÄMMLE, Bernhard; CATALAND, Spero. Thrombotic Thrombocytopenic Purpura: Pathophysiology, Diagnosis, and Management. Clin Med, [S. l.], v. 10, n. 3, p. 536-547, 2 fev. 2021. DOI: 10.3390/jcm10030536. Disponível em: https://pubmed.ncbi.nlm.nih.gov/33540569/. Acesso em: 15 out. 2022.

SWAMI, Arjun; KAUR, Varinder. Von Willebrand Disease: A Concise Review and Update for the Practicing Physician. Clinical and Applied Thrombosis/Hemostasis, [S. l.], v. 23, n. 8, p. 900–910, 2017. DOI: 10.1177/107602961667596. Disponível em:https://journals.sagepub.com/doi/10.1177/1076029616675969. Acesso em: 25 nov. 2022.

ZHENG, X Long. The standard of care for immune thrombotic thrombocytopenic purpura today. J Thromb Haemost, [S. l.], v. 19, n. 8, p. 1864-1871, ago. 2021. DOI: 10.1111/jth.15406. Disponível em: https://pubmed.ncbi.nlm.nih.gov/34060225/. Acesso em: 15 out. 2022.

ZWICKER, Jeffrey et al. Adjuvant low-dose rituximab and plasma exchange for acquired TTP. Blood, [S. l.], v. 134, n. 13, p. 1106-1109, 26 set. 2019. DOI: 10.1182/blood.2019000795. Disponível em: https://pubmed.ncbi.nlm.nih.gov/31331919/. Acesso em: 15 out. 2022.

TREATMENT STRATEGIES FOR THROMBOTIC THROMBOCYTOPENIC PURPURA: AN INTEGRATIVE REVIEW.

UMA REVISÃO INTEGRATIVA.

Authors

Keywords:

Abstract

Author Biography

Matheus Guedes Duarte , Centro Universitário Cenecista de Os´ório/RS

References

Downloads

Published

How to Cite

Issue

Section

License

Language

Information